留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恶性肿瘤出凝血异常机制

寿玮龄 崔巍

寿玮龄, 崔巍. 恶性肿瘤出凝血异常机制[J]. 协和医学杂志, 2012, 3(4): 482-486. doi: 10.3969/j.issn.1674-9081.2012.04.026
引用本文: 寿玮龄, 崔巍. 恶性肿瘤出凝血异常机制[J]. 协和医学杂志, 2012, 3(4): 482-486. doi: 10.3969/j.issn.1674-9081.2012.04.026

恶性肿瘤出凝血异常机制

doi: 10.3969/j.issn.1674-9081.2012.04.026
详细信息
    通讯作者:

    崔巍 电话:010-69154907, E-mail:cuiw@pumch.cn

  • 中图分类号: R73;R364.1+5

  • 表  1  恶性肿瘤患者血栓与止血相关指标实验室检测

    1. TEG
        $ \bullet $对凝血纤溶全过程和血小板功能进行全面评估,鉴别出凝血及纤溶亢进原因
        $ \bullet $指导输血及用药,监测药物疗效
    2.血小板数目与功能检测
       $ \bullet $血小板计数、形态学检查
       $ \bullet $PAdT、PAgT、血小板膜糖蛋白测定、β-TG、PF4、P-选择素
       $ \bullet $TEG platelet mapping
    3.凝血纤溶系统活化标志物
       $ \bullet $凝血因子活化标志物: F1 + 2、FPA、TF、SFMC、凝血因子水平及活性
       $ \bullet $抗凝系统活化标志物: AT-Ⅲ:A、PC:A、PS:A、TAT、TEPI
       $ \bullet $纤溶系统活化标志物: t-PA、u-PA、Fbg、DD、FDP、PAP
    4.血液流变学检查
    5.内皮损伤标志物
       $ \bullet $TM、vWF、ET-1
    TEG:血栓弹力图; PAdT:血小板黏附试验; PAgT:血小板聚集试验; β-TG: β-血小板球蛋白; PF4 :血小板因子4; F1 + 2:纤维蛋白原片段1 + 2; FPA:纤维蛋白肽A; TF:组织因子; SFMC:可溶性纤维蛋白单体复合物; AT-Ⅲ:A:抗凝血酶-Ⅲ活性; PC:A:蛋白C活性; PS:A:蛋白S活性; TAT:凝血酶-抗凝血酶; TEPI:组织因子途径抑制物; t-PA:组织型纤溶酶原活化剂; u-PA:尿激酶型纤溶酶原活化物; Fbg:纤维蛋白原; DD: D二聚体; FDP:纤维蛋白原降解产物; PAP:纤溶酶-α2-抗纤溶酶复合物; TM:血栓调节蛋白; vWF:血管性血友病因子; ET-1:内皮素-1
    下载: 导出CSV
  • [1] Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis[J]. JAMA, 2005, 293:715-722. doi:  10.1001/jama.293.6.715
    [2] Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis[J]. Br J Cancer, 2010, 102(Suppl 1):S2-S9.
    [3] Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolics in cancer patients[J]. Ann Oncol, 2006, 17:297-303. doi:  10.1093/annonc/mdj068
    [4] Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis[J]. Blood, 2002, 100:3484-3488. doi:  10.1182/blood-2002-01-0108
    [5] Særensen HT, Sværke C, Farkas DK, et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer[J]. Eur J Cancer, 2012, 48:586-593. doi:  10.1016/j.ejca.2011.10.032
    [6] Falanga A, Marchetti M. Venous thromboembolism in hematologic malignancies[J]. J Clin Oncol, 2009, 27:4848-4857. doi:  10.1200/JCO.2009.22.8197
    [7] Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism:the Seventh ACCP Conference on antithrombotic and thrombolytic therapy[J]. Chest, 2004, 126(3 Suppl):338S-400S.
    [8] Franchini M, Montagnana M, Targher G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer[J]. J Thromb Thrombolysis, 2007, 24:29-38. doi:  10.1007/s11239-007-0028-6
    [9] Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97:1158-1164. doi:  10.3324/haematol.2011.054718
    [10] Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in caner[J]. J Clin Oncol, 2009, 27:4834-4838. doi:  10.1200/JCO.2009.22.6324
    [11] Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis[J]. J Clin Oncol, 2009, 27:4827-4833. doi:  10.1200/JCO.2009.22.7199
    [12] Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies[J]. Semin Thromb Hemost, 2008, 34:204-210. doi:  10.1055/s-2008-1079262
    [13] Lee AY. Cancer and thromboembolic disease:pathogenic me-chanisms[J]. Cancer Treat Rev, 2002, 28:137-140. doi:  10.1016/S0305-7372(02)00044-0
    [14] Nash GF, Turner LF, Scully MF, et al. Platelets and cancer[J]. Lancet Oncol, 2002, 3:425-430. doi:  10.1016/S1470-2045(02)00789-1
    [15] Aharon A, Brenner B. Microparticles, thrombosis and cancer[J]. Best Pract Res Clin Haematol, 2009, 22:61-69. doi:  10.1016/j.beha.2008.11.002
    [16] Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells:impact on coagulation activation[J]. J Thromb Haemost, 2008, 6:1517-1524. doi:  10.1111/j.1538-7836.2008.02987.x
    [17] De Cicco M. The prothrombotic states in cancer:pathogenic mechanisms[J]. Crit Rev Oncol Hematol, 2004, 50:187-196. doi:  10.1016/j.critrevonc.2003.10.003
    [18] Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancies[J]. J Clin Oncol, 2009, 27:4858-4864. doi:  10.1200/JCO.2009.22.6126
    [19] Baronzio G, Freitas I, Kwaan HC, et al. Tumor microenvironment and hemorheological abnormalities[J]. Semin Thromb Hemost, 2003, 29:489-498. doi:  10.1055/s-2003-44557
    [20] Barbera L, Thomas G. Erythropoiesis stimulating agents, thrombosis and cancer[J]. Radiother Oncol, 2010, 95:269-276. doi:  10.1016/j.radonc.2010.02.008
    [21] Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies[J]. Clin Rheumatol, 2006, 25:840-844. doi:  10.1007/s10067-005-0181-2
    [22] Zacharski LR. Hypercoagulability preceding cancer[J]. J Thromb Haemost, 2005, 3:585-588. doi:  10.1111/j.1538-7836.2005.01178.x
    [23] Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia[J]. N Engl J Med, 1999, 340:994-1004. doi:  10.1056/NEJM199904013401303
    [24] Liu Y, Jiang P, Capkova K, et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy[J]. Cancer Res, 2011, 71:6492-6502. doi:  10.1158/0008-5472.CAN-11-1145
    [25] Otrock ZK, Hatoum HA, Awada AH, et al. Hypoxia-inducible factor in cancer angiogensis:structure, regulation and clinical perspectives[J]. Crit Rev Oncol Hematol, 2009, 70:93-102. doi:  10.1016/j.critrevonc.2009.01.001
    [26] Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis and thrombosis in pancreatic cancer[J]. Clin Cancer Res, 2007, 13:2870-2875. doi:  10.1158/1078-0432.CCR-06-2351
    [27] Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth[J]. Blood, 2008, 111:190-199. doi:  10.1182/blood-2007-07-101048
    [28] Zigler M, Kamiya T, Brantley EC, et al. PAR-1 and thrombin:the ties that bind the microenvironment to melanoma metastasis[J]. Cancer Res, 2011, 71:6561-6566. doi:  10.1158/0008-5472.CAN-11-1432
    [29] McMahon B, Kwaan HC. The plasminogen activator system and cancer[J]. Pathophysiol Haemost Thromb, 2007, 8:184-194.
    [30] 彭黎明, 邓承祺.现代血栓与止血的实验室检测及其应用[M].北京:人民卫生出版社, 2004.
    [31] Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer[J]. J Clin Oncol, 2009, 27:4889-4894. doi:  10.1200/JCO.2009.23.5788
    [32] Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline:recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer[J]. J Clin Oncol, 2007, 25:5490-5505. doi:  10.1200/JCO.2007.14.1283
    [33] Petersen LJ. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients:a review of current guidelines[J]. Cancer Treat Rev, 2009, 35:754-764. doi:  10.1016/j.ctrv.2009.08.009
  • 加载中
表(1)
计量
  • 文章访问数:  142
  • HTML全文浏览量:  28
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-07-20
  • 刊出日期:  2012-10-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!